LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Key Inclusion Criteria: * Treatment naïve patients or those with \<6 months of exposure to nintedanib with physician diagnosed IPF based on ATS/ERS/JRS/ALAT 2018 guidelines * Idiopathic Pulmonary Fibrosis on HRCT, performed within 12 months of Visit 1 as confirmed by central readers * DLCO corrected for Hemoglobin (Hb) \[visit 1\] ≥ 30% and ≤90% of predicted of normal * FVC ≥ 45% of predicted normal Key Exclusion Criteria: * Primary obstructive airway physiology (pre-bronchodilator FEV1/FVC \< 0.7 at Visit 1) * Known explanation for interstitial lung disease, including but not limited to radiation, sarcoidosis, hypersensitivity pneumonitis, bronchiolitis obliterans organizing pneumonia, human immunodeficiency virus (HIV), viral hepatitis, and cancer * Diagnosis of any connective tissue disease, including but not limited to scleroderma/systemic sclerosis, polymyositis/dermatomyositis, systemic lupus erythematosus, and rheumatoid arthritis * Major extrapulmonary physiological restriction (e.g., chest wall abnormality, large pleural effusion) * Cardiovascular diseases, any of the following: * Uncontrolled hypertension, within 3 months of Visit 1 * Myocardial infarction within 6 months of Visit 1 * Unstable cardiac angina within 6 months of Visit 1 * Prior hospitalization for confirmed COVID-19, acute exacerbation of IPF or any lower respiratory tract infection within 3-months of Visit 1